The Top 5 Biosimilar Articles for the Week of April 18

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of April 18, 2022.

Number 5: Number 5: An analysis of real-world dosing and effectiveness of pegfilgrastim biosimilars found the clinical benefits of preventing febrile neutropenia in patients with intermediate to high risk come at acceptable financial costs compared with filgrastim biosimilars.

Number 4: A sub-study assessing the affects of using a prefilled pen vs a prefilled syringe found that the pen was easy for patients to use and was favored by over 90% of patients.

Number 3: New phase 3 data showed Celltrion’s proposed biosimilar of bevacizumab produced an objective response rate equivalent to the reference product Avastin in patients with metastatic or recurrent non-small cell lung cancer.

Number 2: Medicare Part D plans missed out on between $84 million and $143 million in savings by not prioritizing the use of biosimilars over reference products, according to a report from the HHS Office of Inspector General.

Number 1: The FDA approved Amneal Pharmaceuticals’ Biologics License Application (BLA) for bevacizumab-maly, a biosimilar referencing Avastin.

To read all of these articles and more, visit centerforbiosimilars.com.